Every material Form 8-K PharmaCyte Biotech, Inc. has filed with the SEC since December 05, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
PharmaCyte Biotech's Audit Committee dismissed CBIZ CPAs as its independent registered public accounting firm on October 14, 2026, and engaged Grassi & Co., CPAs as its replacement. The filing reports no adverse or qualified audit opinions from CBIZ CPAs for fiscal 2026 and 2025, but it discloses material weaknesses in internal control tied to segregation of duties of the Chief Financial Officer and management review controls.
Dismissal of CBIZ CPAs effective October 14, 2026; CBIZ CPAs' reports for fiscal years ended April 30, 2026 and 2025 contained no adverse opinion, disclaimer, or qualification
Grassi & Co. approved October 14, 2026 to audit fiscal year ending April 30, 2027 and review interim statements starting with the quarter ending October 31, 2026
Disclosed material weaknesses relate to insufficient segregation of duties of the Chief Financial Officer and insufficient management review controls
CBIZ CPAs letter dated October 16, 2026 filed as Exhibit 16.1
At its annual meeting on March 30, 2026, PharmaCyte Biotech stockholders approved five proposals, including authority for the board to effect a reverse stock split at a ratio between 1-for-1.1 and 1-for-100 and a 2,000,000-share increase to the 2022 Equity Incentive Plan. The filing does not say whether the board plans to use the reverse split authority. The meeting also covered director elections, auditor ratification and a non-binding advisory vote on executive pay.
Reverse split authority approved: 5,067,304 votes for, 2,280,497 against, 40,056 abstain; the board may split at 1-for-1.1 to 1-for-100 but is not required to.
Equity plan amended to add 2,000,000 shares: 3,133,280 votes for, 804,435 against, 9,572 abstain.
All five directors nominated, including Joshua N. Silverman, received between 3,397,282 and 3,574,494 votes for; CBIZ CPAs P.C. was ratified as auditor for the year ending April 30, 2026 with 6,837,442 votes for.
Quorum of 7,387,861 shares, about 55.08% of shares entitled to vote, was present; the non-binding say-on-pay proposal drew 3,306,883 votes for and 625,080 against.
PharmaCyte Biotech received a Nasdaq notice on December 1, 2025, saying its common stock no longer meets the $1.00 minimum bid price for continued listing on the Nasdaq Capital Market. The notice has no immediate effect on listing or trading, and the company has until June 1, 2026 to regain compliance, which matters to shareholders because continued failure could lead to delisting.
Nasdaq notice dated December 1, 2025 cites failure to meet the $1.00 minimum bid price under Listing Rule 5550(a)(2)
Compliance Date is June 1, 2026, a 180-day period; regaining compliance requires at least $1.00 closing bid for 10 consecutive business days
Stock continues to trade under PMCB; the company may seek a second 180-day period or consider a reverse stock split subject to stockholder approval
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PharmaCyte Biotech, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →